publication venue for
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. 20:194. 2021
- The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. 20:68. 2021
- Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. 19:175. 2020
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. 19:199. 2020
- Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. 17:154. 2018
- Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. 12:170. 2013
- Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. 7:5. 2008